Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 1, 2014, Pages 97-102

  Yamaue, Hiroki ^a   Satoi, Sohei ^b   Kanbe, Takamasa ^c   Miyazawa, Motoki ^a   Tani, Masaji ^a   Kawai, Manabu ^a   Hirono, Seiko ^a   Okada, Kenichi ^a   Yanagimoto, Hiroaki ^b   Kwon, A Hon ^b   Mukouyama, Tomoyuki ^c   Tsunoda, Hiroaki ^c   Chijiiwa, Kazuo ^d   Ohuchida, Jiro ^d   Kato, Jun ^a   Ueda, Kazuki ^a   Yamaguchi, Taketo ^e   Egawa, Shinichi ^f   Hayashi, Kazuhiko ^g   Shirasaka, Tetsuhiko ^h  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c SAN IN ROSAI HOSPITAL   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e CHIBA CANCER CENTER   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h KITASATO UNIVERSITY   (Japan)

Author keywords

Alternate day; Chemotherapy; Oral therapy; Pancreatic cancer; S 1

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STANDARD; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO TREATMENT; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84892813146     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2323-6     Document Type: Article

References (12)

1. Jemal A, Bray F, Center MM, et al. (2011) Global center statistics. CA Cancer J Clin 61:69-90
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
3. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615-621
4. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31(13):1640-1648
5. Arai W, Hosoya Y, Hyodo M, Yokoyama T, Hirashima Y, Yasuda Y, Nagai H, Shirasaka T (2004) Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol 9:143-148
6. Lipkin M, Sherlock P, Bell B (1963) Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterology 45:721-729
7. Clarkson B, Ota K, Ohkita T, O'Connor A (1965) Kinetics of proliferation of cancer cells in neoplastic effusions in man. Cancer 18:1189-1213
8. Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39:2-15
9. Arai W, Hosoya Y, Haruta H, Kurashina K, Saito S, Hirashima Y, Yokoyama T, Zuiki T, Sakuma K, Hyodo M, Yasuda Y, Nagai H, Shirasaka T (2008) Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo. Int J Clin Oncol 13:515-520
10. Sakuma K, Hosoya Y, Arai W, Haruta H, Ui T, Kurashina K, Saito S, Hirashima Y, Yokoyama T, Zuiki T, Hyodo M, Nagai H, Yasuda Y, Shirasaka T (2010) Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity. Int J Clin Oncol 15:166-171
11. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
12. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063-1069